AAAAAA
Results:
1-13
|
Results: 13
Authors:
Maxwell-Armstrong, CA
Durrant, LG
Buckley, TJD
Scholefield, JH
Robins, RA
Fielding, K
Monson, JRT
Guillou, P
Calvert, H
Carmichael, J
Hardcastle, JD
Citation: Ca. Maxwell-armstrong et al., Randomized double-blind phase II survival study comparing immunization with the anti idiotypic monoclonal antibody 105AD7 against placebo in advancedcolorectal cancer, BR J CANC, 84(11), 2001, pp. 1443-1446
Authors:
Robinson, MH
Rodrigues, VC
Hardcastle, JD
Chamberlain, JO
Mangham, CM
Moss, SM
Citation: Mh. Robinson et al., Faecal occult blood screening for colorectal cancer at Nottingham: detailsof the verification process, J MED SCREE, 7(2), 2000, pp. 97-98
Authors:
Greenberg, PD
Bertario, L
Gnauck, R
Kronborg, O
Hardcastle, JD
Epstein, MS
Sadowski, D
Sudduth, R
Zuckerman, GR
Rockey, DC
Citation: Pd. Greenberg et al., A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy, AM J GASTRO, 95(5), 2000, pp. 1331-1338
Authors:
Bertario, L
Bader, JP
Besbeas, SS
Brevinge, H
Castiglione, G
Crespi, M
Dubois, G
Faivre, J
Fric, P
Giacosa, A
Gnauck, R
Hardcastle, JD
Gutierrez, JMH
Jorgensen, OD
Kronborg, O
Maltoni, G
Wahrendorf, J
Zappa, M
Zavoral, M
Citation: L. Bertario et al., Recommendation to include colorectal cancer screening in public health policy, J MED SCREE, 6(2), 1999, pp. 80-81
Authors:
Watson, SA
Michaeli, D
Morris, TM
Clarke, P
Varro, A
Griffin, N
Smith, A
Justin, T
Hardcastle, JD
Citation: Sa. Watson et al., Antibodies raised by Gastrimmune inhibit the spontaneous metastasis of a human colorectal tumour, AP5LV, EUR J CANC, 35(8), 1999, pp. 1286-1291
Authors:
Moss, SM
Hardcastle, JD
Coleman, DA
Robinson, MHE
Rodrigues, VC
Citation: Sm. Moss et al., Interval cancers in a randomized controlled trial of screening for colorectal cancer using a faecal occult blood test, INT J EPID, 28(3), 1999, pp. 386-390
Authors:
Hardcastle, JD
Citation: Jd. Hardcastle, Helen Allgrove - In appreciation, ANN RC SURG, 81(3), 1999, pp. 122-122
Authors:
Watson, SA
Michaeli, D
Grimes, S
Morris, TM
Varro, A
Clarke, PA
Smith, AM
Justin, TA
Hardcastle, JD
Citation: Sa. Watson et al., A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice, INT J CANC, 81(2), 1999, pp. 248-254
Authors:
Robinson, MHE
Hardcastle, JD
Moss, SM
Amar, SS
Chamberlain, JO
Armitage, NCM
Scholefield, JH
Mangham, CM
Citation: Mhe. Robinson et al., The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer, GUT, 45(4), 1999, pp. 588-592
Authors:
Maxwell-Armstrong, CA
Durrant, LG
Robins, RA
Galvin, AM
Scholefield, JH
Hardcastle, JD
Citation: Ca. Maxwell-armstrong et al., Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7, GUT, 45(4), 1999, pp. 593-598
Authors:
Mapp, TJ
Hardcastle, JD
Moss, SM
Robinson, MHE
Citation: Tj. Mapp et al., Survival of patients with colorectal cancer diagnosed in a randomized controlled trial of faecal occult blood screening, BR J SURG, 86(10), 1999, pp. 1286-1291
Authors:
Hardcastle, JD
Bennett, DH
Reynolds, JR
Vellacott, K
Moshakis, V
Chamberlain, J
Kronborg, O
Besbeas, S
Citation: Jd. Hardcastle et al., A prospective randomised trial comparing flexible sigmoidoscopy and faecaloccult blood testing with faecal occult blood testing alone for colorectalcancer, BIOM HLTH R, 24, 1998, pp. 351-358
Authors:
Robinson, MHE
Hardcastle, JD
Citation: Mhe. Robinson et Jd. Hardcastle, Should we be screening for colorectal cancer?, BR MED B, 54(4), 1998, pp. 807-821
Risultati:
1-13
|